VANCOUVER, BC, Nov. 18, 2021 /PRNewswire/ --Advances in the collective genetic understanding of diseases, and the ability to identify disease biomarkers, is ushering in a new era of personalized medicine. Technologies such as CRISPR/Cas9 are also paving the way for improved, more tailored treatments targeted to a specific genetic marker of a disease. As our understanding of the molecular underpinnings of disease continue to improve, so, too, will the technologies at our disposal to treat them.
We've already seen the benefits of this type of personalized medicine in the cancer realm. Using a person's (or disease's) genes to drive cancer therapy is known as precision medicine. Precision medicine can help doctors identify high-risk cancer patients, choose treatment options, and evaluate treatment effectiveness. Precision medicine can also be used to prevent certain types of cancer, diagnose certain types of cancers early (leading to earlier treatment and better outcomes), and diagnose specific types of cancer more correctly.
As targeted therapies continue to advance, we will continue to see their impacts flow beyond that of the cancer realm. One area in which interest is ramping up is neurodegenerative diseases, which are chronic, progressive diseases affecting the brain and its constituent cells. Neurologic disease can be genetic, or caused by a stroke or brain tumor. Examples of neurodegenerative disease include Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease. These diseases have a genetic component, with specific genes playing a role in the development and progression of disease, especially in rare forms. Neurodegenerative conditions, like cancer, are devastating and costly. Collectively, neurodegenerative conditions cost people in the United States $655 billion in 2020.
Can we apply concepts from targeted therapies developed for cancer to create better outcomes for patients suffering from neurodegenerative diseases? What's more, can precision medicine be used to treat other large unmet needs in the field of neurology, such as neuropsychiatry, pain, epilepsy, sleep disorders, and stroke?
Precision medicine in neuroscience and neurology is where many companies have dedicated their time and efforts. Three companies trading on the NASDAQ in this space that investors should research are Alnylam, Ionis Pharmaceuticals, and Regeneron.
Neuroscience research companies are clamoring to make use of the plethora of cellular and molecular biology data that is emerging about drugs and the patients who use them. There is much more information to be gleaned from diseases and patients than the genetics, which may not reveal information about the ways that genes are formally transcribed and expressed. Emerging technologies, therefore, also look at the RNA profiles of a drug response, patient, or disease state, called transcriptomics; and the set of proteins expressed by a cell, tissue, or organism, called proteomics. While a challenge with gene therapy is reimbursement by insurance providers, research is underway that can make gene therapies more common, and pave the way for more established insurance structures.
RNA targeting is an active area of research for neurodegenerative disease, with companies such as Skyhawk Therapeutics, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, and Takeda involved. By modifying genetic transcription via RNA technologies, these companies hope to develop novel treatments for disorders of the central nervous system. The study of RNA profiles in a given cell, tissue, or organism is known as transcriptomics, and this area will likely heat up as these researchers work to develop pioneering RNA technologies to target neurodegenerative disease.
Proteomics, or the study of the proteins expressed by a cell, tissue, or organism, will also play a role in precision medicine for neurological disorders. In June 2021, the United States Food and Drug Adminstration approved the first therapy addressing the underlying biology of Alzheimer's disease. The drug, Biogen's Aducanumab, is a monoclonal antibody therapy that works by clearing a substance known as beta-amyloid, a protein that scientists believe causes Alzheimer's, from the brain. The drug, which was found to exhibit a unique proteomic profile upon treatment in mice, was the first approved for Alzheimer's in 20 years, and while it is thought to be effective in a limited number of Alzheimer's disease cases (namely, people in the early stages of Alzheimer's), it represents a step forward in neurodegenerative disease research.
The FDA's approval of Aduhelm, which was under an accelerated timeframe, has created more interest in the area of Alzheimer's and Parkinson's disease treatments. Scientists believe that a protein called tau is more closely associated with dementia than beta-amyloid, so they are also seeking to develop drugs targeting tau protein. In the realm of Parkinson's disease, research is underway to target a compound called alpha-synuclein, which, like amyloid beta and tau protein in Alzheimer's, is associated with cognitive decline in Parkinson's disease. There are a number of approaches in development to target tau. Investors can expect many more biotech companies and venture firms moving into this space to develop innovative and alternative treatments.
This work is not without significant challenges. One obstacle in neurodegenerative research is creating drugs that can bypass the brain's blood-brain-barrier, which keeps the brain safe from toxic substances or pathogens that would otherwise make their way into the brain. Another challenge is the fact that neurodegeneration affects a subset of neurons, which may have different levels of vulnerability to such disease. It is not yet fully clear which factors predispose certain neurons to develop pathology over others.
Yet as drug discovery continues to leverage the latest techniques in genomics, transcriptomics, and proteomics, and combinations of these technologies, this will unlock new potential for companies to create novel, increasingly personalized, therapies. For example, advances in genomics may provide insight into how neurodegeneration occurs in the brain.
Drug discovery in neurodegeneration also overlaps with that of other diseases, due to common disease pathways. For example, phosphatidylinositol 3-Kinase (PI3K) inhibitors are implicated not only in COVID-19 and breast cancer, but also Parkinson's Disease. Stem cell therapies, which could benefit patients suffering from many conditions, can also have significant applications in the neurodegenerative realm. Stem cells could potentially be used to restore lost brain tissue, or to release compounds such as anti-inflammatory factors and growth factors supporting repair of the nervous system. Stem cell therapies, which are already in use for conditions such as cancer, could thereby restore function to neurodegenerative patients. Therefore, advances made in the treatment of other disease states could potentially innovate the field of neurodegeneration as well.
PRLog ID: http://www.prlog.org/12894142
SOURCE Braeden Lichti
Go here to see the original:
- Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis - OncLive - January 16th, 2022
- Trial of Cell Therapy to Raise HbF Levels Showing Potential, But... - Sickle Cell Anemia News - January 16th, 2022
- What it's like in academic family medicine: Shadowing Dr. Rouhbakhsh - American Medical Association - January 16th, 2022
- The Fusion of mRNA and Immunotherapy - NEO.LIFE - January 16th, 2022
- Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference - The Bakersfield Californian - January 11th, 2022
- BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference -... - January 11th, 2022
- Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR - Yahoo Finance - January 11th, 2022
- Houston TX Diabetes Stem Cell Treatment Regenerative Medicine Therapy Launch - Digital Journal - January 9th, 2022
- Stem Cell Rejuvenation Center - January 9th, 2022
- Cartesian Aims to Propel RNA Cell Therapy with Combinations - BioSpace - January 9th, 2022
- Orthopedic Biomaterials Product Market: Hip implant product segment is anticipated to carry major share of the market - BioSpace - January 9th, 2022
- Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings - Business Wire - January 9th, 2022
- Jakubowiak Talks Daratumumab Quadruplet Therapy and the GRIFFIN Study at 2021 ASH - Cancer Network - January 9th, 2022
- Part 1: Benefit Shown With Transplant and Combination Therapy in Multiple Myeloma - Targeted Oncology - January 9th, 2022
- Notch Therapeutics' Peter Zandstra Appointed to the Order of Canada - Yahoo Finance - January 7th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVirs Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults... - January 7th, 2022
- BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson's Disease - Yahoo Finance - January 7th, 2022
- Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of CLS001 for Corneal Endothelial Cell Regenerative Therapy - Galveston County... - January 7th, 2022
- US FDA approves Phase 3 Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma - OncoZine - January 5th, 2022
- Alzheimer's Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases - PRNewswire - January 5th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy Designation To AlloVir's Posoleucel For The Treatment Of Adenovirus Infections In Adults And... - January 5th, 2022
- Protecting people with cancer from COVID-19: - EurekAlert - January 5th, 2022
- Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual JP Morgan Healthcare Conference - TheNewswire.ca - January 5th, 2022
- Placental Stem Cell Therapy Market to Surpass US$ 4.4 Bn by 2030, Underpinned by Enormous R&D in Cellular Therapies and Regenerative Medicine, Finds... - January 3rd, 2022
- LifeBank Chain Announces Upcoming Gene and Cell Collaboration Platform With Disrupt Blockchain Technologies - AsiaOne - January 3rd, 2022
- Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity - News-Medical.Net - January 3rd, 2022
- lodie Yung plunges into the undocumented underworld in 'The Cleaning Lady' - Entertainment Weekly News - January 3rd, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 2nd, 2022
- Curi Bio Closes $10M Series A in Oversubscribed Round - BioSpace - December 31st, 2021
- Bring in the bulldozers: Cynatas CEO on how heavyweight FujiFilm will turbocharge its ... - Stockhead - December 31st, 2021
- Questions on Quadruplets and CAR T Set to be Answered As Myeloma Paradigm Parses Out the Clinical Value of MRD - OncLive - December 31st, 2021
- Stem Cell Therapy NYC, Regenerative Medicine Injections ... - December 29th, 2021
- James Shapiro, MD: Insulin Production In T1D Patients After Stem Cell Therapy - MD Magazine - December 29th, 2021
- Global Automated and Closed Cell Therapy Processing Systems - GlobeNewswire - December 29th, 2021
- Bill would pave way for organ donation - Stabroek News - December 29th, 2021
- Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML - BioSpace - December 29th, 2021
- Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T-Cell Leukemia/Lymphoma - Business Wire - December 29th, 2021
- 2021: The Year in Diabetes - Healthline - December 29th, 2021
- Covid infects kidneys and leads to scarring: Study - India New England - December 29th, 2021
- Fetal Gut May Have Insulin-Producing Cells That Shut Off at Birth - Medscape - December 29th, 2021
- Brem Looks at Multiple Treatments for Patients With DLBCL - Targeted Oncology - December 26th, 2021
- Delete Blood Cancer! How Content Creator Duo Abhi And Niyu Inspired Thousands To Give Someone Second... - The Logical Indian - December 25th, 2021
- The pathogenesis, natural history, and treatment of type 1 diabetes: time (thankfully) does not stand still - The Lancet - December 25th, 2021
- Ropinirole Proves Safe and Tolerable for Patients With ALS - Medscape - December 25th, 2021
- Major international research center may drive the development of future stem cell-based treatments - News-Medical.Net - December 19th, 2021
- Receiving CAR-T therapy sooner improves lymphoma survival, according to study published in New England Journal of Medicine - Newswise - December 19th, 2021
- Latest Cancer Research: CAR T to Liquid Biopsies - Healthline - December 19th, 2021
- Trials of stem cell therapy offer hope to childless women in Bangladesh - The Financial Express BD - December 19th, 2021
- UC San Diego Breaks Ground on Revitalization of Hillcrest Campus - UC San Diego Health - December 19th, 2021
- BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition -... - December 19th, 2021
- CAR-T Cell Therapy Continues to Impress in Myeloma Treatment - Curetoday.com - December 17th, 2021
- CAR-T therapy trials show promise for earlier use in lymphoma - BioPharma Dive - December 17th, 2021
- Cedars-Sinai researchers discover growth hormone in the colon that influences aging process - News-Medical.Net - December 17th, 2021
- Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors - Business Wire - December 17th, 2021
- BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of... - December 17th, 2021
- CAR T-Cell Therapy for Large B-Cell Lymphoma Who, When, and How? | NEJM - nejm.org - December 15th, 2021
- Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine... - December 15th, 2021
- AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders -... - December 15th, 2021
- Bioengineered skin breakthrough to revolutionise burns treatment - Medicine, Nursing and Health Sciences - Monash University - December 15th, 2021
- In Patients With Acute GVHD, First-Line Itolizumab Associated With High Rates of Clinical Response, Tolerability - Targeted Oncology - December 15th, 2021
- BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's Phase 3 Study for ALS in Muscle and Nerve - BioSpace - December 15th, 2021
- Flawed genetic switches could be at the origin of malformations or developmental diseases - News-Medical.net - December 15th, 2021
- BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing - BioSpace - December 9th, 2021
- Syrian refugee is thriving five years after last-gasp gene therapy - STAT - STAT - December 9th, 2021
- What happened to Dolly the sheep? How long the first cloned adult mammal lived, and her legacy explained - iNews - December 9th, 2021
- It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India - ETHealthworld.com - December 9th, 2021
- For the 2nd time listed as the World's Top 2% scientists by Stanford University - Malaysiakini - December 9th, 2021
- Research offers a phylogenetic and ontogenetic overview of the primitive streak - News-Medical.net - December 7th, 2021
- New discoveries make steps toward lipoedema diagnosis and treatment - Mirage News - December 7th, 2021
- With its Parkinsons treatment, TreeFrog Therapeutics shows cell therapy is no longer science fiction - The Times Hub - December 7th, 2021
- The lung game: is hyperbaric oxygen therapy any good? - Financial Times - December 7th, 2021
- Irving Weissman Laboratory | Institute for Stem Cell ... - December 4th, 2021
- Nine Things To Know About Stem Cell Treatments - A Closer ... - December 4th, 2021
- Regenerative Medicine & Stem Cell Therapy Las Vegas ... - December 4th, 2021
- World AIDS Day: is a cure for HIV finally in sight? - Thomson Reuters Foundation - December 4th, 2021
- New genetic technology for gene expression analysis of cancer cells - News-Medical.net - December 4th, 2021
- Stem Cell Therapy Restores Insulin Production in Patients with Type 1 Diabetes - MD Magazine - December 4th, 2021
- It takes guts to make a heart - EurekAlert - December 4th, 2021
- Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board - BioSpace - December 4th, 2021
- The Intramural Research Program at the Abu Dhabi Stem Cell Center (ADSCC) Signs a Letter of Intent to Collaborate with the Division of Intramural... - December 4th, 2021